# A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy

> **NCT04663204** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Leicester** · enrollment: 12 (estimated)

## Conditions studied

- Immunoglobulin A Nephropathy
- Kidney Diseases
- Glomerulonephritis, IGA
- Glomerulonephritis
- Autoimmune Diseases
- Immune System Diseases

## Interventions

- **DRUG:** Sparsentan

## Key facts

- **NCT ID:** NCT04663204
- **Lead sponsor:** University of Leicester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-10
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04663204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04663204, "A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04663204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*